Study of a diabetes drug to reduce artery stiffness in veterans with obesity
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests whether an SGLT2 inhibitor (a type of diabetes medication) can help reduce stiffness in the arteries of veterans who have obesity. If you are a veteran aged 30-60 with a BMI of 30-45 and have stiffer arteries than expected for your age, this study might be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a veteran aged 30 to 60 years old.
- Your body mass index (BMI) is between 30 and 45.
- You have stiffer arteries than normal for your age (confirmed by a test).
- You do not have diabetes or any known heart or kidney disease.
- You have not used certain diabetes or weight loss medications in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a diabetes medication called an SGLT2 inhibitor can reduce inflammation in body fat and improve blood vessel function in people with metabolic syndrome. It may help prevent heart disease and other complications.
This study tests an investigational weight-loss medicine called Zenagamtide for people who have heart or blood vessel disease and are overweight or obese. The goal is to see if it can reduce heart-related risks compared to a placebo (a pill with no active medicine).
This study tests if a diabetes medication, empagliflozin, can reduce age-related stiffening of arteries in people without diabetes. If you are between 60 and 80 and have stiff arteries, this trial could help improve your vascular health.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
This trial tests if empagliflozin, a medication typically used for diabetes, can help people with metabolic syndrome (a cluster of conditions like large waist size, high blood sugar, and high blood pressure). It may improve health and reduce the risk of heart disease.
This trial tests canagliflozin to see if it lowers “vascular inflammation” in people with diabetes and stable coronary artery disease. It may help reduce harmful inflammation signals that can raise future heart risk.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.